• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Leung Gabriel was granted 11,215 units of Ordinary Shares, increasing direct ownership by 14% to 92,444 units (SEC Form 4)

    6/6/25 4:21:51 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care
    Get the next $NVCR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LEUNG GABRIEL

    (Last) (First) (Middle)
    C/O NOVOCURE INC.
    1550 LIBERTY RIDGE DRIVE, SUITE 115

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NovoCure Ltd [ NVCR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 06/04/2025 A 11,215 A $0.00 92,444 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $16.72 06/04/2025 A 16,697 06/04/2026(2) 06/04/2035 Ordinary Shares 16,697 $0.00 16,697 D
    Explanation of Responses:
    1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.
    2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.
    Remarks:
    Steven Robbins, as attorney in fact for Leung, Gabriel 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NVCR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVCR

    DatePrice TargetRatingAnalyst
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    12/2/2024$18.00 → $30.00In-line → Outperform
    Evercore ISI
    10/16/2024$24.00 → $30.00Neutral → Buy
    H.C. Wainwright
    11/20/2023$15.00Neutral
    JP Morgan
    8/28/2023$85.00 → $25.00Buy → Neutral
    H.C. Wainwright
    8/8/2023$45.00Neutral → Overweight
    Piper Sandler
    8/4/2023$51.00Outperform
    SVB Securities
    More analyst ratings

    $NVCR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by NovoCure Limited

    SCHEDULE 13G - NovoCure Ltd (0001645113) (Subject)

    8/13/25 12:56:59 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    NovoCure Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    7/24/25 7:02:21 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by NovoCure Limited

    10-Q - NovoCure Ltd (0001645113) (Filer)

    7/24/25 7:01:32 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novocure Reports Second Quarter 2025 Financial Results

    Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "With the first half of 2025 complete, I am pleased

    7/24/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

    TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly delayed the need for opioid pain medication for patients with unresectable, locally advanced pancreatic adenocarcinoma A significant delay in deterioration across measures of health status was observed, preserving quality of life longer in patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel These data complement the previously reported overall survival benefit seen in PANOVA-3, supporting TTFields concomitant with gemcitabine and nab-paclitax

    7/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Report Second Quarter 2025 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.co

    6/30/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/30/25 4:33:06 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NovoCure downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $14.50

    7/25/25 8:59:40 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on NovoCure with a new price target

    Ladenburg Thalmann initiated coverage of NovoCure with a rating of Buy and set a new price target of $30.00

    7/8/25 8:49:22 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    NovoCure upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously

    12/2/24 6:59:42 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/30/25 4:33:06 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Chief Human Resources Officer Puri Michal Nath was granted 833 units of Ordinary Shares, increasing direct ownership by 0.51% to 164,514 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/1/25 4:20:52 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Director Danziger Asaf was granted 833 units of Ordinary Shares, increasing direct ownership by 0.20% to 416,473 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/1/25 4:19:41 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Financials

    Live finance-specific insights

    View All

    Novocure Reports Second Quarter 2025 Financial Results

    Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology Novocure (NASDAQ:NVCR) today reported financial results for the second quarter that ended June 30, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "With the first half of 2025 complete, I am pleased

    7/24/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure to Report Second Quarter 2025 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company's financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.novocure.co

    6/30/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Novocure Reports First Quarter 2025 Financial Results

    Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen Novocure (NASDAQ:NVCR) today reported financial results for the first quarter ended March 31, 2025. Novocure is a global oncology company working to extend survival in some of the most aggressive for

    4/24/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Leadership Updates

    Live Leadership Updates

    View All

    Novocure Appoints Christoph Brackmann as Chief Financial Officer

    Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product

    10/30/24 7:02:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

    Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

    10/18/24 9:00:00 AM ET
    $ENV
    $LH
    $MASI
    Business Services
    Consumer Discretionary
    Medical Specialities
    Health Care

    Novocure Announces Planned CEO Transition

    After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a

    9/3/24 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    $NVCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/10/24 1:14:41 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by NovoCure Limited

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    7/8/24 4:32:39 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by NovoCure Limited (Amendment)

    SC 13G/A - NovoCure Ltd (0001645113) (Subject)

    2/13/24 5:09:51 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care